Abstract Number: PO124
Meeting: ISTH 2021 Congress
Background: Antithrombin as thrombin inhibitor inhibits also activated coagulation factors IX, X, XI, XII, kalikrein and plasmin. Deficiency of antithrombin confers 3-7-fold increased risk of the venous thromboembolism (VTE) in the comparison with other thrombophilic states. Antithrombin deficiency may be inherited or acquired. Inherited form is rare thrombophilic state inherited in an autosomal dominant manner.
Aims: To present a case of patient with demanding management of repeated thrombotic complications and antithrombin deficiency.
Methods: The authors present the study of the patient with mild antithrombin deficiency. Despite this non-severe form of antithrombin activity, repeated thrombotic events were developed. Therefore, the authors discuss risk factors, diagnosis and treatment possibilities of this thrombophilia.
Results: During the last year, antithrombotic management improved the quality of life of the patient who has been the last year without further thrombotic complications.
Conclusions: Antithrombin deficiency is a high-risk and quite rare thrombophilia. Despite adequate anticoagulation, repeated thrombosis can occur and has severe clinical consequences. Thus, the close monitoring of the patient is inevitable.
Acknowledgements: Authors thank the support of the projects of the Scientific Grant Agency (Vega) 1/0549/19 and Agency for the Support of Research and Development APVV-16-0020.
To cite this abstract in AMA style:Stanciakova L, Holly P, Palova J, Brunclikova M, Dobrotova M, Bolek T, Samos M, Kubisz P, Stasko J. Recurrent Thrombosis and Antithrombin Deficiency [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1). https://abstracts.isth.org/abstract/recurrent-thrombosis-and-antithrombin-deficiency/. Accessed September 24, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/recurrent-thrombosis-and-antithrombin-deficiency/